PDF下载 ( 1209 KB)
Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma
-
摘要: <正>原发性肝癌在全球发病率已超过62.6万/年,居于恶性肿瘤发病率的第5位;病死率也接近60万/年,位居肿瘤相关死亡的第3位[1]。我国发病人数约占全球的55%,其中85%～90%为肝细胞癌,严重威
-
Key words:
- radiofrequency ablation /
- hepatocellular carcinoma /
- sorafenib
-
[1]王志明, 周乐杜, 吕秀生, 等.原发性肝癌治疗方法的选择:附265例报告[J].中国普通外科杂志, 2004, 13 (12) :908-911. [2] 中华医学会肝病学会分会肝癌学组.原发性肝癌规范化诊治的专家共识[J], 内科理论与实践, 2009, 4 (4) :353-360. [3]Llovet JM, Bruix J.Molecular targeted therapies in hepato-cellular carcinoma[J].Hepatology, 2008, 48 (4) :1312-1327 [4]郭武华, 张吉翔.肝癌综合治疗的现状[J].世界华人消化杂志, 2008, 16 (20) :2199-2203. [5]Llovet J, Ricci S, Mazzaferro V, et al.Sorafenib improvessurvival in advanced hepatocellular carcinoma (HCC) :Re-sults of a phase III randomized placebo-controlled trial (SHARP trial) [J].J Clin Oncol, 2007, 25:LBAl. [6]Liu L, Cao Y, Chen C, et al.Sorafenib blockes the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and in-duces tumor cell apoptosis in hepatocellular carcinoma modelPLC/PRF/5[J].Cancer Ras, 2006, 66 (24) :11851-11858. [7]Cheng AL, Kang YK, Chen Z, et al.Efficacy and safety ofsorafenib in patients in the Asia-Pacific region with ad-vanced hepatocellular carcinoma:a phase III randomized, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34. [8]Strumberg D, Awada A.Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced sol-id tumours:Is rash associated with treatment outcome?[J].Eur J Cancer, 2006, 42 (4) :548-556. -
本文二维码
计量
- 文章访问数: 2258
- HTML全文浏览量: 15
- PDF下载量: 670
- 被引次数: 0
下载:
